David Grayzel, MD
Dr. David Grayzel is co-founder and member of the Board of Directors of Surface Oncology, and is a Partner at Atlas Venture. Since joining Atlas Venture in 2010, Dr. Grayzel co-founded and served as CEO of Arteaus Therapeutics, LLC which was acquired by Eli Lilly in 2014, as well as co-founder and CEO of Annovation Biopharma Inc. which was acquired by The Medicines Company in early 2015. He is currently a co-founder and acting CEO of Ataxion, founding board member of Delinia and co-founder of Quartet Medicine. Previously, he was a member of the executive team at Infinity Pharmaceuticals and was responsible for all clinical research activities as the head of clinical development and medical affairs.
Dr. Grayzel obtained his BA from Stanford University, his MD from Harvard Medical School and completed his internship and residency training in internal medicine at Massachusetts General Hospital. David serves on the board of Acera: The Massachusetts School for Science, Creativity, and Leadership, a STEM focused K-8 school, which he and his wife Courtney started in 2009. David also serves as an advisor to Memorial Sloan Kettering Cancer Center’s Technology Development Fund, a member of the Tri-Institutional TDI Antibody SAB, and founding member of the American Heart Association’s One Brave Idea team.